CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Jazz Pharmaceuticals plc

JAZZ
$15.34BLarge Cap

Next catalyst

PDUFAApr 16, 2027in 150 days

Cannabidiol

Sturge-Weber Syndrome

Get an email about JAZZ's next catalysts

Track Jazz Pharmaceuticals (JAZZ) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 5 more upcoming events in our data (conference, Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

6 upcoming, 1 past

Conference

Conference Presentation

Nov 17, 2026

ET. The article text is truncated and other conferences (e.g., Piper) are not fully detailed.

Source
Phase 2

CPX-351 Phase 2 Est. Readout

December 2026~CPX-35124

Estimated primary completion for CPX-351 trial (NCT04990102) in Acute Myeloid Leukemia (AML) in Remission. Topline data typically follows completion by weeks to months.

Source
Phase 2

Defibrotide Phase 2 Est. Readout

December 2026~Defibrotide42

Estimated primary completion for Defibrotide trial (NCT04652115) in Covid19. Topline data typically follows completion by weeks to months.

Source
Phase 2

Zanidatamab Phase 2 Est. Readout

December 2026~Zanidatamab200

Primary completion for Zanidatamab trial (NCT06695845) in Breast Cancer

Source
PDUFANext

FDA PDUFA Date oral cannabidiol capsule

Apr 16, 2027Cannabidiol

NDA filing. Extracted from SEC filing: EX-99.1

Source
Phase 3

CPX-351 Phase 3 Est. Readout

June 2027~CPX-351882

Estimated primary completion for CPX-351 trial (NCT03897127) in Acute Myeloid Leukemia. Topline data typically follows completion by weeks to months.

Source

Upcoming FDA decisions

How JAZZ's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsBiotechnology🇺🇸EuropeDUBLIN2.8K employees

Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Website
Drug Pipeline

Xyrem (sodium oxybate) oral solution

Phase 3

Fibromyalgia

Xyrem

Phase 3

Narcolepsy With Cataplexy

Dordaviprone (ONC201)

Phase 3

H3 K27M

Sodium Oxybate

Phase 3

Essential Tremor

IM JZP-458

Phase 3

Acute Lymphoblastic Leukemia

a benzodiazepine drug

Phase 3

Anxiety Disorder

JZP-258

Phase 3

Idiopathic Hypersomnia

Nabiximols

Phase 3

Pain

THC Alone

Phase 3

Palliative Care

GW-1000-02

Phase 3

Pain

Modafinil at established dose

Phase 3

Narcolepsy

Sodium Oxybate & 6 Tablets

Phase 3

Fibromyalgia

ONC201

Phase 3

Diffuse Intrinsic Pontine Glioma

JZP926 capsule

Phase 3

Juvenile Myoclonic Epilepsy

Zanidatamab

Phase 3

HER2-positive Breast Cancer

Sativex®

Phase 3

Spasticity

JZP-110

Phase 3

Obstructive Sleep Apnea

Brincidofovir

Phase 3

Adenovirus Infection

Xywav

Phase 3

Narcolepsy

GWP42003-P

Phase 3

Epilepsy

CPX-351

Phase 3

Acute Myeloid Leukemia (AML)

7+3 (cytarabine and daunorubicin)

Phase 3

High Risk Acute Myeloid Leukemia

Xyrem®

Phase 3

Fibromyalgia

Defibrotide

Phase 3

Severe Hepatic Veno-Occlusive Disease

IV JZP-458

Phase 3

Acute Lymphoblastic Leukemia

experimental anti-anxiety drug

Phase 3

Anxiety Disorder

Sativex

Phase 3

Multiple Sclerosis

GW-2000-02

Phase 3

Pain

Sodium Oxybate Oral Solution (6 grams)

Phase 3

Fibromyalgia

Vyxeos

Phase 3

Acute Myeloid Leukaemia

Custodiol

Phase 3

Coronary Artery Stenosis

Sodium Oxybate & 8 Tablets

Phase 3

Fibromyalgia

Busulphan

Phase 3

Acute Myeloid Leukaemia

CPX-315

Phase 2

Acute Myeloid Leukemia

TTX-MC138

Phase 2

HER2-positive Breast Cancer

Liposome-encapsulated Daunorubicin-Cytarabine

Phase 2

Recurrent Acute Myeloid Leukemia

Dociparstat sodium

Phase 2

Acute Myeloid Leukemia

Suvecaltamide

Phase 2

Parkinson Disease

Lurbinectedin

Phase 2

Refractory Ewing Sarcoma

GWP42006

Phase 2

Epilepsy

ZW25 (Zanidatamab)

Phase 2

HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Recombinant Granulocyte Colony-Stimulating Factor

Phase 2

Acute Myeloid Leukemia

GWP42003

Phase 2

Schizophrenia

Evorpacept

Phase 2

HER2-expressing Cancers

GWP42004

Phase 2

Dyslipidemias

JZP385

Phase 2

Essential Tremor

Intensive Salvage Therapy

Phase 2

Acute Myeloid Leukemia

ONC206: Dose 1

Phase 2

Advanced Pheochromocytoma and Paraganglioma

ONC206: Dose 2

Phase 2

Advanced Pheochromocytoma and Paraganglioma

Clobazam

Phase 2

Epilepsy

DNX-2401

Phase 2

Diffuse Intrinsic Pontine Glioma

Clonazepam

Phase 2

Epilepsy

Daunorubicin

Phase 2

Acute Myeloid Leukemia

CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection

Phase 2

Colorectal Neoplasms

CX-8998

Phase 2

Epilepsy

JZP150

Phase 2

Post Traumatic Stress Disorder

ADX-N05

Phase 2

Narcolepsy

asparaginase Erwinia chrysanthemi

Phase 2

Acute Lymphoblastic Leukemia

ONC206

Phase 2

Advanced Pheochromocytoma and Paraganglioma

mFOLFOX

Phase 2

Gastroesophageal Adenocarcinoma

Cytarabine and Idarubicin

Phase 2

Acute Myeloid Leukemia

Cannabidivarin

Phase 2

Autism Spectrum Disorder

CBD Oral Solution

Phase 2

Fragile X Syndrome

Bicarbonate de sodium

Phase 2

Hematologic Disease

Glasdegib

Phase 2

Acute Myelogenous Leukemia (AML) Due to Therapy

Cannabidiol

Phase 2

Sturge-Weber Syndrome

Epidiolex

Phase 2

Sturge - Weber Syndrome (SWS)

Enasidenib Mesylate

Phase 2

Recurrent Acute Myeloid Leukemia

MHA

Phase 2

Myeloid Neoplasm

Frequently asked questions

What is in Jazz Pharmaceuticals plc's drug pipeline?→

CatalystAlert tracks 69 drug candidates in Jazz Pharmaceuticals plc's (JAZZ) pipeline across Phase 3, Phase 2. Its lead program is Cannabidiol (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Jazz Pharmaceuticals plc's next FDA catalyst?→

Jazz Pharmaceuticals plc's (JAZZ) next tracked catalyst is a PDUFA date expected Apr 16, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track JAZZ biotech catalysts?→

Add JAZZ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jazz Pharmaceuticals plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply